Stricken US college student corroborates red flag raised to 29,000 pharmacists Feb. 27, 2023 Dear Friends: Spraying finasteride on your scalp instead of ingesting it is no guarantee you won’t develop post-finasteride syndrome (PFS). So cautions Germany’s oldest and most widely read pharmaceutical journal. So, too, an American college senior who says his academic, social […]
Dec. 4, 2022 Dear Friends: French PFS awareness is going high-tech. ANSM, the Gallic nation’s drug-regulatory authority (DRA), last week unveiled plans to add a so-called “red-box” warning—that includes a QR code—on all finasteride 1 mg products in 2023. Intended to “reinforce information on adverse effects” of Propecia and generics, the warning reads: This medication […]
Reporter calls disclosure by nation’s drug-regulatory agency ‘shocking and unbelievable’ Nov. 2, 2022 Dear Friends: Anti-finasteride sentiment continues to run rife on Teutonic TV. Dürfen Die Das? (Can They Do That?), a newsmagazine show on the German public-broadcasting network NDR, last week debuted a 17-minute film titled Finasteride: Why Is This Hair-loss Drug Still on […]
Study marks first-ever demonstration of a successful PFS therapy in an animal model Oct. 29, 2022 Dear Friends: The neurosteroid allopregnanolone (ALLO) has proved effective in counteracting some of the finasteride-induced alterations in gut microbiota, according to new research at the University of Milano (UniMi). Titled Gut Inflammation Induced by Finasteride Withdrawal: Therapeutic Effect of […]
Israeli pharmacovigilance expert, meanwhile, calls for ‘revolution’ in ADR reporting after local family of PFS suicide case files suit against Merck Sept. 26, 2022 Dear Friends: If you’ve ever Googled “post-finasteride syndrome,” chances are you’ve earned a place in the annals of medicine. Researchers at the University of Southern California’s Keck School of Medicine (KSM) […]
But Patient Product Information not revised to include the potentially lethal adverse events Aug. 29, 2022 Dear Friends: Organon & Co., the Merck & Co. spinoff that now owns Propecia (finasteride 1 mg), has added a new adverse drug reaction (ADR) to the hair-loss remedy’s label: suicidality. Earlier this month, Organon updated the Adverse Reactions […]